Gossamer Bio

Update in progress

GOSS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Gossamer Bio is a clinical-stage biopharmaceutical company focused on seralutinib for pulmonary hypertension and pulmonary arterial hypertension in the United States. It develops GB002, an inhaled small-molecule inhibitor targeting PDGFR, c-KIT, and related pathways, currently in Phase 3 for PAH. The company has a license with Pulmokine to develop and market GB002 and back-up compounds. Formerly FSG, Bio, Inc., it was renamed in 2017. Founded in 2015 and based in San Diego, California.

Company score

Sentiment: 0.21; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive